Table 3

Comparison of baseline characteristics and antipyretic treatments of survivors and non-survivors

Patients with sepsis

Patients without sepsis


Survivors

(N = 471)

Non-survivors

(N = 135)

P-value

Survivors

(N = 783)

Non-survivors

(N = 36)

P-value


Gender (male) n (%)

291 (61.8%)

94 (69.6%)

0.10

485 (61.9%)

23 (63.9%)

0.81

Age (y.o., IQR)

67 (54, 75)

69 (58, 78)

0.08

64 (54, 73)

74.5 (59, 81.5)

0.003

APACHE (IQR)

20 (16, 24)

24 (21, 28)

< 0.001

13 (10, 18)

24 (19.5, 28)

< 0.001

Postoperative admission n (%)

59 (12.5%)

9 (6.7%)

0.057

523 (66.8%)

11 (30.6%)

< 0.001

Mechanical ventilation requirement n (%)

317 (67.3%)

112 (83.0%)

< 0.001

498 (63.6%)

30 (83.3%)

0.016

Reasons for admission n (%)

Cardiac or vascular diseases

93 (19.7%)

16 (11.9%)

0.04

422 (53.9%)

13 (36.1%)

0.04

Thoracic or respiratory diseases

253 (53.7%)

90 (66.7%)

0.007

193 (24.6%)

12 (33.3%)

0.24

Renal or metabolic disease

48 (10.2%)

13 (9.6%)

0.85

51 (6.5%)

3 (8.3%)

0.67

Gastrointestinal tract diseases

56 (11.9%)

12 (8.9%)

0.33

102 (13%)

6 (16.7%)

0.53

Other

21 (4.5%)

4 (3%)

0.44

15 (1.9%)

2 (5.6%)

0.13

Length of stay in ICU

8 (5, 14)

9 (5, 15)

0.74

5 (4, 7)

5 (4, 9)

0.11


NSAIDs

Number of patients n (%)

(Un adjusted odds ratio (95% CI))

19 (4%)

12 (8.9%)

0.02

98 (12.5%)

1 (2.8%)

0.08

(2.32 (1.10, 4.91))

(0.20 (0.03, 1.47))

Delta body temperature* (°C, IQR)

-0.4 (-0.9, -0.1)

-0.1 (-0.6, 0.0)

0.08

-0.4 (-0.7, 0)

0.0 (0.0, 0.0)

0.30


Acetaminophen n (%)

Number of patients n (%)

(Un adjusted odds ratio (95%CI))

75 (15.9%)

41 (30.4%)

0.002

31 (4%)

1 (2.8%)

0.72

(2.30 (1.48, 3.58))

(0.69 (0.09, 5.23))

Delta body temperature* (°C, IQR)

-0.4 (-1.1, -0.1)

-0.4 (-0.9, -0.2)

0.94

-0.3 (-0.7, 0.0)

-0.9 (-0.9, -0.9)

0.28


Cooling n (%)

Number of patients n (%)

(Unadjusted odds ratio (95%CI))

223 (47.3%)

64 (47.4%)

0.99

366 (46.7%)

18 (50%)

0.74

(1.00 (0.68, 1.46))

(1.14 (0.58, 2.22))

Delta body temperature* (°C, IQR)

-0.2 (-0.4, 0)

-0.2 (-0.5, 0)

0.55

-0.1 (-0.3, 0)

-0.1 (-0.4, 0)

0.16


APACHE, Acute Physiology and Chronic Health Evaluation; CI, confidential interval; IQR, 25%, 75% interquartile; NSAIDs, non-steroid anti-inflammatory drugs

*, Delta body temperature from application of antipyretic to next temperature monitoring

Fever and Antipyretic in Critically ill patients Evaluation (FACE) Study Group et al. Critical Care 2012 16:R33   doi:10.1186/cc11211

Open Data